Inactivation of specific tumor suppressor genes by transcriptional silencing associated with hypermethylation of the promoter is a common event in cancer. We have applied the amplification of intermethylated sites (AIMS) technique to a 100 human colorectal cancers and seven cell lines to identify recurrent alterations that may unveil silenced tumor suppressor genes. Bisulfite sequencing was used to confirm differential DNA methylation results. Gene expression analysis was performed by real-time RT-PCR. An AIMS band recurrently displayed in tumors but not in normal tissues was isolated and identified as part of the CpG island of the prostacyclin synthase (PTGIS) gene promoter. PTGIS promoter was hypermethylated in 43 out of 100 colorectal cancers and in all cell lines. Bisulfite sequencing and clonal analysis confirmed the results obtained by AIMS and demonstrated biallelic hypermethylation of PTGIS promoter. Hypermethylation of the PTGIS promoter was associated with diminished gene expression, that was restored after treatment with demethylating and histone deacetylases inhibitor agents. PTGIS hypermethylation was associated with aneuploidy and p53 mutations. In the adjusted model, PTGIS methylation, but not p53 mutation, maintained the association with aneuploidy. We conclude that epigenetic inactivation of the PTGIS gene is a recurrent alteration in colorectal carcinogenesis. Oncogene(2005) 24, 7320-7326.
Introduction
Aberrant hypermethylation in the promoter region of different genes is a common feature of most cancers and appears to be associated with transcriptional silencing of the contiguous gene (Jones and Baylin, 2002) . Epigenetic inactivation is involved through different elements in all the signaling pathways disrupted in human carcinogenesis (Jones and Baylin, 2002) . Therefore, the characterization of the methylome in normal and pathologic tissues is one of the most demanding challenges in human genome projects and will be instrumental for the development of diagnostic tools and the design of specific therapies. Amplification of intermethylated sites (AIMS) (Frigola et al., 2002) generates methylome fingerprints by the simultaneous screening of a large number of selectively amplified methylated sequences. When series of cases including normal and colorectal tumor samples are analysed, the characterization of recurrently altered sequences may help in unveiling novel targets relevant to human carcinogenesis. Characterization of one of the AIMSgenerated sequences showing recurrent differential representation between normal and tumor tissue revealed the frequent methylation of the prostacyclin synthase (PTGIS) gene promoter in neoplastic samples, indicating its putative epigenetic silencing associated with malignant transformation.
A key regulatory step in the synthesis of prostaglandins is the enzymatic conversion of arachidonic to PGH2 by COX1 and COX2, the latter frequently overexpressed in human colorectal tumors. Inhibition of the COX pathway has been considered a prime target in multiple preventive and therapeutic designs, mainly in colorectal tumors (Brown and DuBois, 2005) . PGH2 is subsequently converted to distinct prostaglandins. The synthesis of one of these prostaglandins, the prostacyclin or PGI 2 , is catalysed by PTGIS. PGI 2 appears to exert antiproliferative effects (Lim and Dey, 2002) and to have chemopreventive properties (Brown and DuBois, 2005) . Furthermore, intracellular PGI 2 has been shown to promote apoptosis by activating the endogenous PPARd receptor (Hatae et al., 2001; Lim and Dey, 2002) . We have pursued further characterization of the methylation profile of the PTGIS gene in a series of cell lines and colorectal cancers and its association with the clinical and molecular features of the tumors.
Results

AIMS screening
From the fingerprints obtained by AIMS, we identified a double band (tagged T1) that showed a consistent overrepresentation in tumors as compared to the respective normal tissues (Figure 1a) , indicating differential hypermethylation. Specifically, 40 out of 90 tumors (44%) and three out of 10 adenomas (30%) showed a noticeable increase in the intensity of the band when compared to the paired normal tissue. T1 band was also clearly present in all the colorectal cell lines analysed suggesting that this sequence was strongly methylated. The doublet was isolated, cloned, sequenced, and identified by BLAST alignment as a DNA fragment comprising a part of the CpG island located in the PTGIS promoter. Only one of the two SmaI sites flanking the T1 band was inside of the CpG island (Figure 1b) .
High-resolution methylation analysis of the PTGIS promoter
The methylation profile of the CpG island located at the 5 0 end of the PTGIS gene was characterized by bisulfite sequencing in two adenomas (one displaying T1 band and one lacking T1 band in the AIMS fingerprints), five carcinomas (three displaying T1 band and two lacking T1 band), together with the respective paired normal mucosa (all without T1 band), and seven colon cancer cell lines. First, a 316 bp region (Fragment A) spanning 21 CpGs at the 3 0 end of the CpG island and including part of the AIMS T1 band was amplified by PCR ( Figure 1b) . From each sample, 10 different clones were sequenced. CpGs outside the CpG island were methylated in all normal tissues, but the 16 CpGs within the CpG island were sparsely methylated. These CpGs were densely methylated in tumors exhibiting hypermethylation of PTGIS gene as revealed by AIMS, but not in tumors with no change in the AIMS fingerprint as compared to normal tissue (Figure 1c) , demonstrating that AIMS differential display was associated with changes in the DNA methylation of the CpG island. Therefore, the relative increase in the intensity of the AIMS T1 band detected in 40 tumors and three adenomas was interpreted as an indicator of methylation of the CpG island.
To confirm this interpretation we analysed an inner fragment of the CpG island. A 412 bp long sequence spanning 40 CpG sites (Fragment B) was amplified by PCR, cloned and sequenced (Figure 1b) . The CpG methylation profiles of five normal-tumor pairs and two adenomas are shown in Figure 2 . Dense hypermethylation was clearly evidenced in carcinomas 138T, 99T and 72T and adenoma A2, all of them with a clear display of the T1 band in the AIMS fingerprint. Carcinomas 69T and 127T and adenoma A1, lacking T1 band, were unmethylated. In summary, a perfect correlation between the differential representation of the AIMS T1 band and the methylation profile of the CpG island ascertained by bisulfite sequencing was found in all the samples analysed. The sequencing of the CpG island also allowed the genotyping of a polymorphism consisting in four or six repetitions of a nine nucleotide sequence (Amano et al., 2004) . As illustrated in Figure 2 , the sequencing of cloned PCR products confirmed the methylated status of the two alleles in heterozygous samples (99T and A2). Moreover, bisulfite sequencing revealed dense methylation (75-100%) of almost all CpG sites in all cell lines analysed (Figure 3 ).
Analysis of PTGIS expression
We determined if hypermethylation of the PTGIS promoter was associated with a downregulation of expression. PTGIS expression levels were determined by real-time RT-PCR in 15 normal-tumor pairs including the samples on which we had previously performed a detailed characterization of the CpG island methylation profile. Four tumors with unmethylated PTGIS CpG island showed upregulated expression when compared to normal tissue (Figure 4a ), suggesting that cell transformation enhances PTGIS gene expression. Downregulation of PTGIS expression was observed in tumors showing extensive promoter hypermethylation, except for one case that was upregulated (Figure 4a ). 
Restoration of PTGIS expression in colon cancer cells
Colorectal cancer cell line HCT116 that showed complete hypermethylation and undetectable levels of PTGIS expression was cultured with the demethylating agent 5Aza and the histone deacetylase inhibitor TSA. Interestingly, either treatment was able to induce the reexpression of the PTGIS, but the highest levels of gene expression were observed when the cell line was cultured with both agents (Figure 4b ). As expected, the PTGISassociated CpG island was completely demethylated after treatment with both agents (see Supplementary  Figure) .
PTGIS hypermethylation and clinicopathological and molecular features
The possible association of the PTGIS promoter methylation status with different characteristics of the tumors was investigated. No significant differences were found regarding age, sex, tumor location, Dukes' stage, K-ras mutation or microsatellite instability (Table 1) . Noteworthy, there was a highly significant association between hypermethylation of the PTGIS promoter and p53 mutations and aneuploidy (Table 1) . The association between p53 mutations and aneuploidy was weaker (P ¼ 0.062). When a multivariate adjusted model was analysed, PTGIS methylation retained its association with aneuploidy (odds ratio 3.23, CI95% 1.08-9.70, P ¼ 0.03) but not p53 mutation (odds ratio 1.76, CI95% 
Discussion
In a previous study, the application of the methylome fingerprinting technique AIMS allowed us to detect hypomethylation and hypermethylation signatures in a large series of colorectal carcinomas when compared to their paired normal colonic mucosas (Frigola et al., 2005) . Moreover, because the AIMS-generated markers can be isolated and individually characterized, this approach is also suitable for the identification of recurrent epigenetic alterations in cancer (Frigola et al., 2002; Paz et al., 2003; Sadikovic et al., 2004) . Here, we describe the PTGIS promoter hypermethylation in colorectal cancer as a paradigm of one of these epigenetic changes. PTGIS hypermethylation has been confirmed by bisulfite sequencing, its functional implications demonstrated at gene expression level, and its involvement in colorectal tumorigenesis unveiled by the differential features of tumors with and without epigenetic inactivation of the PTGIS gene. The bisulfite characterization of the DNA region represented in AIMS revealed that although the SmaI site restricting the differential amplification is in the boundary of the CpG island, the quantitative nature of the AIMS technique allows the detection of differences in the density of CpG methylation. The analysis of the CpG island core including the transcription start site of Gene expression analyses revealed that hypermethylation of the PTGIS promoter was associated with downregulation of the transcript, as expected. On the contrary, tumors with unmethylated CpG island showed an enhanced expression of the PTGIS gene. A discordant result was also found in one tumor (Figure 4a , case 15), with an increased expression of PTGIS in spite of exhibiting a heavily methylated promoter. This result may be explained by contamination by normal tissue, heterogeneity in the tumor, monoallelic inactivation, and a gene expression normalization problem. Colon cancer cell lines exhibited undetectable levels of the transcript in a context of a very dense hypermethylation. The link between promoter hypermethylation and epigenetic silencing of the PTGIS gene was directly tackled by demonstrating that treatment with the demethylating drug 5Aza and TSA, a specific inhibitor of the histone deacetylases, also resulted in the reactivation of PTGIS. The combined treatment with the two agents was highly synergistic in inducing the PTGIS expression as it has been demonstrated for other genes (Cameron et al., 1999; Yang et al., 2001; Ghoshal et al., 2002) , and supports the notion that both DNA and histone modifications participate in the regulation of gene expression. Altogether, these results suggest that methylation of the PTGIS promoter is likely to play an important role in colorectal cancer.
Different investigations have highlighted the importance of the PTGIS expression in preventing tumor growth and progression (Keith et al., 2002; Pradono et al., 2002; Cutler et al., 2003; Keith et al., 2004) . It has been suggested that some of the protective effects of PTGIS overexpression may be attributable to apoptosis activation mediated by PPARd (Hatae et al., 2001) . Recent studies have also reported that PPARd may promote intestinal adenoma growth (Gupta et al., 2004) , revealing the important, but also complex, involvement of this pathway in colorectal cancer. In our setting, we found that PTGIS promoter hypermethylation was strongly associated with the presence of p53 mutations, as well as aneuploidy (Table 1) . The association between p53 mutations and aneuploidy was weaker, pointing out that PTGIS epigenetic silencing may be a direct effector in the induction or facilitation of chromosomal instability in cancer cells. Available data are insufficient to ascertain the molecular mechanisms underlying the observed correlations, but it is possible that PTGIS is involved in the cell's response to genomic damage, probably by resistance to apoptosis mediated by PPARd (Hatae et al., 2001) . The relevance of PTGIS inactivation in colorectal cancer is further reinforced by its early occurrence in tumor progression, its age-independent nature and the strong tumor specificity of the methylation process. Full understanding of the causes and implications of PTGIS inactivation in colorectal cancer requires a comprehensive study of the different elements of the COX-2 pathway, their interactions, and their consequences on the cell's biology.
In conclusion, we have shown the suitability of the AIMS approach to discover new epigenetic targets in cancer. For the first time, we report the hypermethylation of the PTGIS promoter as a common event in colorectal cancer. The PTGIS promoter methylation profile has been characterized by AIMS and bisulfite sequencing and the functional implications, namely transcriptional silencing, have been demonstrated in primary tumors and cell lines. Furthermore, this inactivation is strongly associated with p53 mutation and aneuploidy. Therefore, we propose that PTGIS gene inactivation may play an important role in colorectal cancer progression with putative direct implications in chromosomal instability and avoidance of apoptosis. It is obvious that after these results, a new line of therapeutic strategies based on the reactivation of PTGIS activity or the administration of prostacyclin analogs can be hypothesized in an important subset of colorectal cancers. Future studies should elucidate the relevance of this approach.
Materials and methods
Samples
In all, 90 colorectal carcinomas, with their paired nonadjacent areas of normal colonic mucosa, and 10 colorectal adenomas, synchronous with carcinomas included in the former series, were collected as fresh-frozen tissues within 2 h of removal and then stored at À801C. All samples were obtained from the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). The study protocol was approved by the Ethics Committee. A total of 90 colorectal carcinomas used in this study were characterized previously for mutations in the p53 and K-ras genes (Tortola et al., 1999) , and aneuploidy (Risques et al., 2001) . Human colorectal carcinoma cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
AIMS screening
We used the AIMS method to screen for tumor-specific alterations. AIMS method is based on the differential cleavage of isoschizomers with distinct methylation sensitivity and the selective amplification of short sequences (up to B1 kb long) flanked by two methylated SmaI (CCCGGG) sites that are ligated to an adaptor and a specific 3-4 nucleotide sequence (adjacent to the SmaI site) arbitrarily chosen by the investigator. Lack of methylation at either site prevents amplification of the band. The AIMS-generated sequences can be tagged, isolated, and individually characterized. All samples were analysed using the set of primers (set A) and conditions described previously (Frigola et al., 2002 ). An illustrative example is shown in Figure 1a . A sequence (displayed as a double band) appearing differentially methylated in AIMS fingerprints was excised from a fresh dried polyacrylamide gel, reamplified, cloned, and sequenced to ascertain the unique identity of the isolated band.
Methylation analysis
To confirm the methylation status of the PTGIS gene promoter, we performed genomic bisulfite sequencing under conditions described previously (Clark et al., 1994) . On the basis of the functional promoter sequence (Yokoyama et al., 1996) , two different fragments of the CpG island (857 bp) were amplified by nested PCR to improve the quality of the electropherograms (Grunau et al., 2001) . Fragment A was located at the 3 0 end of the PTGIS gene CpG island and included one of the SmaI sites from the AIMS sequence. Fragment B covered the first exon of the gene and the central part of the CpG island (Figure 1 ). Primers sequence is described in Table 2 . PCR conditions may be obtained from the authors. In all, 10 individual clones were sequenced from each PCR reaction.
Gene expression analysis
RNA was extracted using the phenol-chloroform method. Quantitative real-time PCR was performed in a LightCycler apparatus (Roche Diagnostics SL Applied Science). Reaction was performed using primers covering exons 5 and 6 of the PTGIS gene (Table 2) , and the LCFastStart DNA Master SYBR Green I reagent set (Roche Diagnostics SL Applied Science) according to the manufacturer's instructions. The reaction was performed in triplicate. The amplified products were sequenced to confirm the identity. The expression levels of PTGIS gene in normal-tumor pairs were normalized according to the average of 18s rRNA, b2-Microglobuline, and cyclophilin expression levels. However, cyclophilin expression was modified by TSA treatment and was not considered in the normalization of PTGIS expression in TSA treatment. A relative calibration curve was constructed for each gene using five serial dilutions starting with 100 ng of RNA.
Restoration of PTGIS expression in HCT116 colon cancer cells
Cells were treated for 24 h with 0.5 mm 5-Aza-2 0 -deoxycytidine (5Aza) (Sigma, St Louis, MO, USA). After the treatment, the medium was replaced with fresh medium and the cells were cultured for a further 48 h before harvesting. Cells were treated for 24 h with trichostatin A (TSA) (Sigma) at 25, 50, and 100 nmol/l or an identical volume of ethanol. For cotreatment, cells were treated with 5Aza for 24 h, after which the medium was removed and TSA was added for a further 24 h. The concentrations and the treatment conditions used were chosen based on preliminary studies showing optimal reactivation of gene expression.
Statistical analysis
Statistical differences between variables were analysed with unpaired/paired t-tests or analysis of variance (ANOVA), as appropriate. Contingency tables were analysed by the w 2 or Fisher's exact test, as appropriate. Logistic regression models were used for multivariate analyses of binary traits. Two-tailed P-values below 0.05 were considered to be statistically significant. 
